Welcome to our dedicated page for Nolato news (Ticker: NLTBF), a resource for investors and traders seeking the latest updates and insights on Nolato stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nolato's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nolato's position in the market.
Nolato reported strong results for Q1 2021, with sales increasing to SEK 2,645 million, up from SEK 2,065 million. Operating profit (EBITA) surged to SEK 308 million, with an EBITA margin of 11.6%. Profit after tax reached SEK 226 million, and diluted earnings per share climbed to SEK 8.43. Medical Solutions saw a notable 17% organic growth, while Integrated Solutions achieved 40% growth. The company plans to expand production capacity in multiple countries, responding to strong demand across business areas.
FAQ
What is the market cap of Nolato (NLTBF)?
